Topic

Articles

Ken Shimokawa, Founder and General Partner of G4S Capital, shares insights into what venture capitalists look for when evaluating emerging biopharmaceutical opportunities.




How Emerging Biopharmas Can Obtain VC Funding

Natalie Douglas talks about her experience in the area of managed and expanded access and her new venture, RareiTi.

Managed Access to Rare Disease Medicines

Leela Barham is a freelance health economist and policy expert. She has published in peer-reviewed journals and presented at national and international conferences. She has provided advice to the Department of Health and Social Care on policy on pricing of branded medicines to inform the negotiation of a successor to the UK’s Pharmaceutical Price Regulation Scheme (PPRS), the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), as well as worked with patient groups, the NHS, pharmaceutical companies and many others internationally on the economics of healthcare and pharmaceuticals. Contact Leela on leels@btinternet.com

Leela Barham talks to Dr. Brian O’Rourke, outgoing President and Chief Executive Officer of the Canadian Agency for Drugs and Technologies in Health (CADTH), about his 11 in years in the role.

Putting CADTH on the National and International Stage

Led in part by its new head of the Americas business, Sebastian Guth, Bayer went all in in 2019 on expanding pursuits in science and discovery, striking deals with 11 digital health startups and upping investment in disease-detection programs and patient engagement and education.   

Paving Bayer’s Future Path

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

AstraZeneca's Joris Silon outlines the company's efforts in CVRM (Cardiovascular, Renal and Metabolism) and the potential impact on type-2 diabetes and chronic kidney disease of SGLT2 inhibitors such as Forxiga.


AstraZeneca's CVRM Path

Hari Pujar, chief technology officer of Spark Therapeutics, discusses the unique manufacturing and scale-up challenges involved with cell and gene therapy production.

Deeper Dive: Gene Therapy Manufacturing

Korn Ferry's Dr. Paul Pospisil talks to HBSHAA's Michael Wong about why biopharma employees should be excited about the industry's prospects.

Planning Ahead with Korn Ferry's Dr. Paul Pospisil

Lundbeck executive Taj Bhardwaj talks about the differing mindsets necessary to lead local and global-level market access strategy in pharma-and how his current company is committed to stay in the fight to advance new treatments and break down stigmas in mental health.

Lundbeck's Taj Bhardwaj: Market Access and Mental Health

Amy Mahery, last month appointed Global Head of Market Access and Pricing of the healthcare business of Merck KGaA, Darmstadt, Germany, discusses her key priorities and how she will draw on her multi-faceted industry experience to approach the challenges ahead.

Unprecedented Times for Market Access: Amy Mahery

Aiforia Technologies CEO Kaisa Helminen talks about the benefits of pharma embracing digital technologies, especially AI-assisted image analysis in the field of histopathology.

Executive Profiles